The next generation of Covid-19 vaccines under development may come as a pill or nasal spray and be easier to store and transport than the current handful of photos that are at the heart of vaccination efforts around the world.
These newer vaccines from U.S. government labs and companies, including Sanofi SA, Altimmune Inc. and Gritstone Oncology Inc. also have the potential to provide longer-lasting immune responses and be more potent against newer and more viral variants that could possibly help overcome future pandemics, the companies say.
Currently, vaccines approved for use in the United States by Pfizer Inc. and its partner BioNTech SE, as well as Moderna Inc., must be transported and stored at low temperatures and require two doses administered per week.
The new vaccines could “represent some improvement”
There are 277 Covid-19 vaccines being developed worldwide, 93 of which have been tested in humans, according to the World Health Organization. Most vaccines are injected in clinical trials, but there are two oral formulations and seven nasal sprays.